Research progress on predictive indicators of a clinical cure for chronic hepatitis B
10.3760/cma.j.cn501113-20241015-00541
- VernacularTitle:慢性乙型肝炎临床治愈预测指标的研究进展
- Author:
Ruyi ZHANG
1
;
Wei YUE
;
Ling ZHU
;
Jinbo LUO
;
Bing BU
;
Yilan WANG
;
Yameng WANG
;
Jiawei GENG
Author Information
1. 云南省第一人民医院 昆明理工大学附属医院感染性疾病及肝病科,昆明 650100
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Hepatitis B surface antigen;
Hepatitis B virus core antibody;
Hepatitis B virus core antigen-associated antigen;
Hepatitis B virus RN
- From:
Chinese Journal of Hepatology
2025;33(5):500-504
- CountryChina
- Language:Chinese
-
Abstract:
Nucleotide analogues (NAs) and interferon are still the first-line drugs for the treatment of chronic hepatitis B (CHB), but they still cannot completely eliminate covalently closed circular DNA (cccDNA) within hepatocytes. The clinical cure, or the disappearance of HBsAg, is the ideal goal of antiviral therapy. Although interferon therapy has a significantly greater HBsAg clearance rate and seroconversion rate than NAs, combination or sequential treatment can improve the HBsAg clearance rate and seroconversion rate to a certain extent, and only a small proportion of CHB patients can achieve clinical cure. Therefore, finding indications that predict clinical cure before and during antiviral treatment is crucial for identifying patients who are more likely to achieve HBsAg clearance at an early stage, improving clinical cure rates, and reducing treatment costs. This article reviews the research progress on predictive indicators of clinical cure of chronic hepatitis B in the past five years, explores the value of each indicator in predicting clinical cure, and provides a reference for optimizing CHB treatment strategies.
